![Logo for NewAmsterdam Pharma Company N.V.](/_next/image?url=https%3A%2F%2Ffiles.quartr.com%2Fcompany-logos%2F96821-2023-12-21-08-14-21.png&w=256&q=100)
NewAmsterdam Pharma Company Investor Relations Material
Latest events
![Logo for NewAmsterdam Pharma Company N.V.](/_next/image?url=https%3A%2F%2Ffiles.quartr.com%2Fcompany-logos%2F96821-2023-12-21-08-14-21.png&w=128&q=100)
Study Update
NewAmsterdam Pharma Company
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from NewAmsterdam Pharma Company N.V.
Access all reports
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company based in the Netherlands, focusing on the development of oral and non-statin medicines for patients at high risk of cardiovascular disease. Its leading product candidate is obicetrapib, a next-generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, currently in various stages of clinical trials. The company's mission is aimed at improving patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated, with a significant focus on creating a potent, cost-effective, and convenient LDL-lowering therapy. The company is headquartered in Naarden, the Netherlands, and its shares are listed on the Nasdaq.
Key slides for NewAmsterdam Pharma Company N.V.
![CETP knock - in mice](/_next/image?url=https%3A%2F%2Fcdn.quartr.com%2Fimages%2Fconference-calls%2Fnewamsterdam-pharma-company-nv-corporate-presentation-e72afdfab51dff1b%2F26.png&w=3840&q=75)
![Logo for NewAmsterdam Pharma Company N.V.](/_next/image?url=https%3A%2F%2Ffiles.quartr.com%2Fcompany-logos%2F96821-2023-12-21-08-14-21.png&w=128&q=100)
Corporate Presentation
NewAmsterdam Pharma Company N.V.
![Statistically Signif](/_next/image?url=https%3A%2F%2Fcdn.quartr.com%2Fimages%2Fconference-calls%2Fnewamsterdam-pharma-company-nv-study-update-0334ee6fdfcab6af%2F8.png&w=3840&q=75)
![Logo for NewAmsterdam Pharma Company N.V.](/_next/image?url=https%3A%2F%2Ffiles.quartr.com%2Fcompany-logos%2F96821-2023-12-21-08-14-21.png&w=128&q=100)
Study Update
NewAmsterdam Pharma Company N.V.
Latest articles
![Key](/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F182663%2F2000x1125%2Fbbbaafadba%2Fpontis-dackmo_strong-opinions-loosely-held.png&w=3840&q=75)
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
![Key](/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F182663%2F2000x1125%2F7455f6afd1%2Fnovo-nordisk_the-danish-pharmaceutical-titan.png&w=3840&q=75)
Novo Nordisk: The Danish Pharmaceutical Titan Revolutionizing Global Healthcare
Novo Nordisk's rise to becoming Europe's largest company, reshaping global healthcare and Denmark's economy.
5 Sep 2024
![Key](/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F182663%2F2000x1125%2F5533bee49f%2Fthe-toyota-way.png&w=3840&q=75)
The Toyota Way: Revolutionizing Global Manufacturing
Explore how Toyota's Lean Manufacturing and Kaizen principles revolutionized production and quality, setting global benchmarks for excellence.
2 Sep 2024
Ticker symbol
NAMS
Country
🇺🇸 United States